The need for transformative medicines is greater than ever. At Prothena, we integrate scientific insights around neurological dysfunction and the biology of misfolded proteins to advance a diverse pipeline of novel therapeutics.
We follow the science. Fueled by a deep scientific expertise built over decades, our research has led to foundational discoveries related to diseases caused by protein dysregulation.
Now is the time. Significant evidence suggests antibodies that optimally target misfolded proteins can result in clinically meaningful benefit for patients. With a growing pipeline of programs based on this scientific approach, Prothena is advancing therapeutics for neurodegenerative and rare peripheral amyloid diseases, which affect millions of people and their families worldwide.
Learn more about some of Prothena’s ongoing clinical trials: the Phase 3 AFFIRM-AL (birtamimab) trial is now enrolling patients with Mayo Stage IV AL amyloidosis; the Phase 1 ASCENT (PRX012) study is evaluating an investigational therapeutic for patients with Alzheimer’s disease.
